How to buy Aptevo Therapeutics stock (APVO)

Aptevo Therapeutics is a biotechnology business based in the US. Aptevo Therapeutics shares (APVO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.41 – an increase of 7.82% over the previous week. Aptevo Therapeutics employs 40 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Aptevo Therapeutics stock

Buy Aptevo Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Aptevo Therapeutics stock price (NASDAQ: APVO)

Use our graph to track the performance of APVO stocks over time.

Aptevo Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$4.41
52-week range	$3.65 - $399.60
50-day moving average more info button	$8.78
200-day moving average more info button	$35.92
Wall St. target price	$296.00
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-415.99

Is it a good time to buy Aptevo Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aptevo Therapeutics price performance over time

Historical closes compared with the close of $4.41 from 2024-12-20

1 week (2024-12-13)	7.82%
1 month (2024-11-22)	1,333.21%
3 months (2024-09-20)	2,492.59%
6 months (2024-06-21)	729.10%

1 year (2023-12-22)	2,207.69%
2 years (2022-12-22)	-99.87%
3 years (2021-12-22)	12975.1616
5 years (2019-12-20)	12535.5932

Aptevo Therapeutics financials

Gross profit TTM	$3.1 million
Return on assets TTM	-72.75%
Return on equity TTM	-250.96%
Profit margin	0%
Book value	$0.26
Market Capitalization more info button	$2.1 million

TTM: trailing 12 months

Aptevo Therapeutics share dividends

We're not expecting Aptevo Therapeutics to pay a dividend over the next 12 months.

Have Aptevo Therapeutics's shares ever split?

Aptevo Therapeutics's shares were split on a 1:37 basis on 3 December 2024 . So if you had owned 37 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aptevo Therapeutics shares – just the quantity. However, indirectly, the new 3600% higher share price could have impacted the market appetite for Aptevo Therapeutics shares which in turn could have impacted Aptevo Therapeutics's share price.

Aptevo Therapeutics share price volatility

Over the last 12 months, Aptevo Therapeutics's shares have ranged in value from as little as $3.65 up to $399.6. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aptevo Therapeutics's is 5.066. This would suggest that Aptevo Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aptevo Therapeutics overview

Aptevo Therapeutics Inc. , a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG. APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.

Frequently asked questions

null
What percentage of Aptevo Therapeutics is owned by insiders or institutions?
Currently 0.028% of Aptevo Therapeutics shares are held by insiders and 11.357% by institutions. How many people work for Aptevo Therapeutics?
Latest data suggests 40 work at Aptevo Therapeutics. When does the fiscal year end for Aptevo Therapeutics?
Aptevo Therapeutics's fiscal year ends in December. Where is Aptevo Therapeutics based?
Aptevo Therapeutics's address is: 2401 4th Avenue, Seattle, WA, United States, 98121 What is Aptevo Therapeutics's ISIN number?
Aptevo Therapeutics's international securities identification number is: US03835L2079 What is Aptevo Therapeutics's CUSIP number?
Aptevo Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03835L207